Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A. - Wikidata - wikimedia - TriplyDB

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.

http://www.wikidata.org/entity/Q28281249

about

Brivaracetam: a rational drug discovery success story Profile of brivaracetam and its potential in the treatment of epilepsy Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond Brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base [Brivaracetam for add-on treatment in focal epilepsy].The potential of antiseizure drugs and agents that act on novel molecular targets as antiepileptogenic treatments.Brivaracetam differentially affects voltage-gated sodium currents without impairing sustained repetitive firing in neurons SVOP is a nucleotide binding protein.Expression of SV2 isoforms during rodent brain development.Perspectives on treatment options for mesial temporal lobe epilepsy with hippocampal sclerosis.Emerging drugs for partial-onset epilepsy: a review of brivaracetam Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies.New and investigational antiepileptic drugs.Levetiracetam: a comprehensive review.New developments in the management of partial-onset epilepsy: role of brivaracetam.Emerging drugs for partial onset seizures.Pharmacotherapy of epilepsy: newly approved and developmental agents.Brivaracetam for the treatment of epilepsy.Triheptanoin--a medium chain triglyceride with odd chain fatty acids: a new anaplerotic anticonvulsant treatment?Brivaracetam for the treatment of epilepsy in adults.The preclinical discovery and development of brivaracetam for the treatment of focal epilepsy.Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures.Brivaracetam for the treatment of epilepsy.Brivaracetam in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.Brivaracetam: First Global Approval.Brivaracetam: Rationale for discovery and preclinical profile of a selective SV2A ligand for epilepsy treatment.Brivaracetam: An Adjunctive Treatment for Partial-Onset Seizures.Brivaracetam: A Review in Partial-Onset (Focal) Seizures in Patients with Epilepsy.Antiepileptic Drug Discovery and Development: What Have We Learned and Where Are We Going?The efficacy and safety of brivaracetam at different doses for partial-onset epilepsy: a meta-analysis of placebo-controlled studies.Progress report on new antiepileptic drugs: A summary of the Thirteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XIII).Synaptic Vesicle-Recycling Machinery Components as Potential Therapeutic Targets.Effect of Rifampin on the Disposition of Brivaracetam in Human Subjects: Further Insights into Brivaracetam Hydrolysis.Clavulanic acid does not affect convulsions in acute seizure tests in mice.Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action.Brivaracetam, a Novel Antiepileptic Drug: Is it Effective and Safe? Results from One Phase III Randomized Trial.Anticonvulsant effects of a triheptanoin diet in two mouse chronic seizure models Brivaracetam disposition in mild to severe hepatic impairment.Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial.Acute and long-term effects of brivaracetam and brivaracetam-diazepam combinations in an experimental model of status epilepticus.

P2860

Q24642768-9875592B-C9A8-43DA-8134-011B5D132B9E Q26776317-FD377EF1-647C-4222-BCD8-B5978ADDF941 Q28068507-2A1CA0CE-6187-454B-B2E2-567086E95560 Q28076065-24A10CFC-5E36-4DEA-B852-F00D62C79F3F Q30390285-21007CBA-F238-42D4-96B4-43E19D9B304D Q30576758-71E78F41-79A4-4FB1-A755-0B583C7106E7 Q30627739-8399A0C1-2545-4DE9-9F4F-33244F848993 Q33434528-2A52F90B-34FC-4074-9F93-61725902ADB9 Q34927836-1DB1136D-2795-4237-8F65-25CD714E4779 Q35761335-EA777E05-48DA-4A17-8794-9BE104E79345 Q36891212-5F3C4D6F-02F1-4282-8736-3A67B9964DA9 Q37113376-E0065E30-FD99-436F-AA07-A1F163D85648 Q37638688-7735FFB9-E7D9-403F-BA21-775C2ECE1CE1 Q37688063-ADA6B164-8A7E-4BC7-A66F-31034A22DD4E Q37693757-3AE4860F-6317-443A-8B81-F4E092049B93 Q37754477-9BDB99C8-D6C9-456E-BDD9-D1EB23A383EB Q37831297-C0E4346F-6DA1-4180-8025-160B33A3656E Q37891095-434F256A-7A83-4257-B693-A686DFAA34B8 Q37920144-FEABA94C-9698-4099-82F2-1FEB7C9B9CD9 Q38195636-FD06427E-9380-42BA-A611-D9B145A22273 Q38614499-F5F3B7F8-C806-42C9-A318-18A520A83F28 Q38626838-82A2452B-736F-4432-9E20-14D0BD4BBE27 Q38694479-B9CAF560-FFF4-448D-A169-D62F594F641B Q38739649-921495A8-7456-4D0C-BBD9-0FCF1FCB61FE Q38743281-BC1791B2-E9AE-48ED-A4AA-68645DA56804 Q38752407-D9FB1A0E-FB3D-4C31-B349-F8655E799757 Q38844513-725040B1-6E62-409A-A2D7-6062F1773C20 Q38922348-6AE90B68-D657-4343-8427-7E85FD57E218 Q38974450-3A17C7B1-C789-49D9-B29B-3C215EE24EC9 Q38985697-5A9F46B1-5596-4988-852D-E5CF2AE5F21F Q39006241-373629C4-B1EF-4919-9A06-9D2576DD68E0 Q39164408-6343107C-B827-4A9D-AF4A-7D0A117B6F6F Q39899497-BC547837-BB06-433E-AC5E-C1DA28C981CE Q40135754-9F3777BA-8CDB-4D74-ABC9-52994A8E86FC Q40215881-97671674-EBDC-4BC4-8CE6-93CDAA3C8497 Q41877287-13E9D0E0-678F-42DF-8EC8-BCFD1DDC2662 Q42409348-BEDBDADD-6E91-49A4-95DD-CC11CC43A4EA Q44231616-A944D16D-FCB3-44FE-8C02-F142AF503984 Q44773924-026501C2-B595-4B49-B676-4AFABFA2A2F2 Q46010938-A6F6B7B5-2A4A-4E23-88E7-D32E46F6A34A

P2860

Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A.

http://www.wikidata.org/entity/Q28281249

description

2008 nî lūn-bûn

@nan

2008 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

name

Anti-convulsive and anti-epile ...... synaptic vesicle protein, SV2A

@nl

Anti-convulsive and anti-epile ...... ynaptic vesicle protein, SV2A.

@ast

Anti-convulsive and anti-epile ...... ynaptic vesicle protein, SV2A.

@en

type

label

Anti-convulsive and anti-epile ...... synaptic vesicle protein, SV2A

@nl

Anti-convulsive and anti-epile ...... ynaptic vesicle protein, SV2A.

@ast

Anti-convulsive and anti-epile ...... ynaptic vesicle protein, SV2A.

@en

prefLabel

Anti-convulsive and anti-epile ...... synaptic vesicle protein, SV2A

@nl

Anti-convulsive and anti-epile ...... ynaptic vesicle protein, SV2A.

@ast

Anti-convulsive and anti-epile ...... ynaptic vesicle protein, SV2A.

@en

P1433

Q28281249-C0536833-5355-4AC2-AD04-E24CA16F689F

P1476

Q28281249-6D95B9CC-1BC2-4270-B43D-AD301EDD363B

P2093

Q28281249-35A50681-AAB5-4B3A-A7ED-01A80B0B36B3

Q28281249-40B0E1E0-E231-4F0A-BB70-AB797D76D873

Q28281249-458335F4-3B31-4825-9B77-D8A4A91D7FA4

Q28281249-581F78B7-DD39-4976-B5D5-E7C5A000FDE7

Q28281249-8741AB7D-FB2E-4762-89EA-5DDF139CE767

P2860

Q28281249-1C6F2E60-FE52-4671-AC67-993851405836

Q28281249-24485BB9-C977-42A8-AFA9-01C1EFF75A9E

Q28281249-2B65C3D0-806C-4A3D-A4C0-A8319F3202EB

Q28281249-2C438405-7B21-4682-BDCD-E00A07EC10AA

Q28281249-355A9C8F-3E7B-424C-A8B6-4B2F441BC7F8

Q28281249-36D6E4E2-5F04-45FC-A89D-E704B55F2972

Q28281249-3A408CF8-7BDA-46B3-8D58-2B9D2CF01B9A

Q28281249-4A248FD5-6289-4904-A9C2-A2591B859EAA

Q28281249-5E146FB3-7D88-438E-BB1C-8EF04E7F6D30

Q28281249-6BF00D3E-00B4-4F61-B64D-17CEB095401B

P304

Q28281249-02DD51C8-91E5-4C96-86D2-0C1AFA6B6343

P31

Q28281249-26F8FAE1-1B4A-44D4-9A22-A7FD3C658369

P3181

Q28281249-6CE464E9-5199-4771-A97D-E505C89A6EAE

P356

Q28281249-5E5436BD-9A0B-4FBA-A867-432A7D4A110C

P407

Q28281249-EF0F884D-F83E-4FC7-88F1-FF9A462CCEC3

P433

Q28281249-C919C0FD-D952-47AC-8CB4-BA6102DCDC39

P478

Q28281249-8886B07D-438B-4D7F-8E42-B72E04D8705F

P577

Q28281249-2043D50E-114C-43D1-8237-8DBB6F855BE1

P5875

Q28281249-024C54A9-E87B-4285-BA0C-6AE615A48C4B

P698

Q28281249-08913161-5913-4091-8013-C4DE7BED88C3

P932

Q28281249-2BDB4B72-B6C9-437D-85DA-57A890ACA3F0

P3181

P356

P1433

British Journal of Pharmacology

P1476

Anti-convulsive and anti-epile ...... ynaptic vesicle protein, SV2A.

@en

P2093

A Matagne

http://www.w3.org/2001/XMLSchema#string

B Kenda

http://www.w3.org/2001/XMLSchema#string

D-G Margineanu

http://www.w3.org/2001/XMLSchema#string

H Klitgaard

http://www.w3.org/2001/XMLSchema#string

P Michel

http://www.w3.org/2001/XMLSchema#string

P2860

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam

Molecular targets for antiepileptic drug development

Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs

Modification of seizure activity by electrical stimulation. II. Motor seizure

The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents

Levetiracetam: the preclinical profile of a new class of antiepileptic drugs?

Use of epileptic animals for adverse effect testing.

Disease modification in partial epilepsy.

Strategies in antiepileptic drug development: is rational drug design superior to random screening and structural variation?

The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males.

P304

1662-1671

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1310725

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/BJP.2008.198

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

154

http://www.w3.org/2001/XMLSchema#string

P577

2008-05-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5350571

http://www.w3.org/2001/XMLSchema#string

P698

18500360

http://www.w3.org/2001/XMLSchema#string

P932

2518465

http://www.w3.org/2001/XMLSchema#string